Singapore markets closed

Precision BioSciences, Inc. (DTIL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.3000-0.0100 (-0.76%)
At close: 04:00PM EDT
1.3800 +0.08 (+6.15%)
After hours: 07:15PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.3100
Open1.3200
Bid1.3200 x 3200
Ask1.3300 x 2200
Day's range1.3000 - 1.4100
52-week range1.1100 - 11.6100
Volume403,630
Avg. volume1,672,508
Market cap144.063M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Precision BioSciences to Participate in Upcoming Jefferies Cell & Genetic Medicine Summit

    DURHAM, N.C., September 22, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the Jefferies Cell & Genetic Medicine Summit taking place September 29-30, 2022.

  • Business Wire

    Precision BioSciences to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference

    DURHAM, N.C., September 07, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022.

  • Business Wire

    Precision BioSciences Announces Senior Leadership Organizational Changes

    DURHAM, N.C., September 02, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced promotions and organizational changes that impact responsibilities within the company’s senior leadership team reporting to Michael Amoroso, Chief Executive Officer (CEO).